Download MendeleyDevelopment of a novel class of potent and selective FIXa inhibitors.
Zhang, T., Andre, P., Bateman, T.J., Chen, Y.H., Desai, K., Ellsworth, K., Geissler, W.M., Guo, L., Hruza, A., Jian, T., Meng, D., Parker, D.L., Qian, X., Reichert, P., Sherer, E.C., Shu, M., Smith, C.J., Sonatore, L.M., Tschirret-Guth, R., Nolting, A.F., Orr, R., Campeau, L.C., Araki, K., Nishimura, T., Sakurada, I., Wood, H.B.(2015) Bioorg Med Chem Lett 25: 4945-4949
- PubMed: 25978966
- DOI: https://doi.org/10.1016/j.bmcl.2015.04.057
- Primary Citation of Related Structures:
4ZAE - PubMed Abstract:
Using structure based drug design (SBDD), a novel class of potent coagulation Factor IXa (FIXa) inhibitors was designed and synthesized. High selectivity over FXa inhibition was achieved. Selected compounds demonstrated oral bioavailability in rat IV/PO pharmacokinetic (PK) studies. Finally, the pharmacodynamics (PD) of this class of molecules was evaluated in Thrombin Generation Assay (TGA) in Corn Trypsin Inhibitor (CTI) citrated human plasma and demonstrated characteristics of a FIXa inhibitor.
Organizational Affiliation:
Department of Medicinal Chemistry, Merck Research Laboratories, Merck & Co., Inc., PO Box 2000, Rahway, NJ 07065, USA. Electronic address: ting_zhang3@merck.com.
